Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France’s AAC

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced the appointment of José Iglesias, M.D. as Chief Medical Affairs Officer, effective November 10, 2025. Dr. Iglesias will lead global medical affairs for botensilimab (BOT) and balstilimab (BAL) as the combination advances through Phase 3 evaluation and becomes available in selected countries through early-access mechanisms, including France’s Autorisation d’Accès Compassionnel (AAC) program.

BOT is an Fc-enhanced multifunctional CTLA-4 antibody and BAL is a PD-1 antibody. In combination, BOT/BAL is being investigated in patients with microsatellite-stable colorectal cancer (MSS CRC), a population that has historically derived limited benefit from immunotherapy despite substantial unmet medical need.

Dr. Iglesias brings over 30 years of global oncology and immuno-oncology drug development experience. Previously, at Abraxis BioScience and Celgene, he led late-stage development and life-cycle management of Abraxane in pancreatic, lung, and metastatic breast cancers, supporting its integration into routine practice across these tumor types. Most recently, Dr. Iglesias served in senior medical leadership roles at Bionomics, Biothera, and Apobiologix, where he directed global oncology programs across biologics, small molecules, and immunotherapies.

In his new role, Dr. Iglesias will oversee global medical affairs strategy for BOT/BAL, including medical evidence generation, communications, and scientific exchange with clinicians, investigators, and health authorities. He will also guide appropriate use of BOT/BAL within regulatory and early-access frameworks worldwide, including France’s AAC program, with a focus on robust data collection and real-world evidence.

France has granted BOT/BAL AAC authorization for MSS colorectal cancer, enabling eligible patients to access the combination with full government reimbursement under the national early-access framework. Hospitals and treating physicians in France have already begun submitting AAC requests, and treatment has been initiated. This AAC authorization complements existing and planned named-patient and early-access programs in additional geographies, where Agenus is pursuing access under local regulations. Under Dr. Iglesias’ leadership, medical affairs will support appropriate use, physician education, and real-world evidence across these pathways.